EHR

Loyal Now Available on Oracle Healthcare Marketplace

New availability helps enable expanded digital integration for personalized consumer experience directly in Oracle Health’s EHRATLANTA--(BUSINESS WIRE)--Loyal, a leading consumer…

2 years ago

Suki Extends the Capabilities of its Developer Platform With SDK and APIs to Power Voice AI Experiences

Bond Vet becomes the first customer to integrate Suki’s voice AI capabilities into its EHR using SDK for a more…

2 years ago

IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)

Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June…

2 years ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half…

2 years ago

Keros Therapeutics to Host a Corporate Update Conference Call and Webcast

LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company…

2 years ago

RadiusXR Achieves ISO 13485 and MDSAP Certifications, Announces Expansion into Canadian Market

PLEASANTON, Calif.--(BUSINESS WIRE)--#Ophthalmology--RadiusXR, a leading innovator in digital health technology, is proud to announce that it has received ISO 13485…

2 years ago

AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June…

2 years ago

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer

Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk…

2 years ago

nference to Present AI-Driven Research at 2024 ASCO Annual Meeting

AI workflow enhances precision of progression-free survival estimates in metastatic breast cancer, enabling more effective and personalized treatmentsCAMBRIDGE, Mass.--(BUSINESS WIRE)--nference,…

2 years ago

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR…

2 years ago